Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

(2017) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them

(2017) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

(2017) Riccardo Lencioni et al.   JOURNAL OF HEPATOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1

(2016) M. Gavanier et al.   EUROPEAN JOURNAL OF RADIOLOGY

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

(2016) Jorge A. Marrero et al.   JOURNAL OF HEPATOLOGY

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

(2016) María Reig et al.   JOURNAL OF HEPATOLOGY

Change of the peripheral blood immune pattern and its correlation with prognosis in patients with liver cancer treated by sorafenib

(2016) Chang-Jiang Lei et al.   Asian Pacific Journal of Tropical Medicine

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

(2015) Massimo Iavarone et al.   HEPATOLOGY

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Systemic treatment

(2014) Maria Reig et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib

(2014) Satoshi Shiba et al.   HEPATOLOGY RESEARCH

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

(2014) Maria Reig et al.   JOURNAL OF HEPATOLOGY

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

(2014) M. Ronot et al.   ONCOLOGIST

Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST

(2014) Maria Reig et al.   SEMINARS IN LIVER DISEASE

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice

(2013) Yunching Chen et al.   HEPATOLOGY

Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) C. Verslype et al.   ANNALS OF ONCOLOGY

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

(2011) Massimo Iavarone et al.   HEPATOLOGY

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Hypoxia and Inflammation

(2011) Holger K. Eltzschig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Regulation and Function of NF-κB Transcription Factors in the Immune System

(2009) Sivakumar Vallabhapurapu et al.   Annual Review of Immunology

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

(2009) Giuseppe Cabibbo et al.   HEPATOLOGY

NF-κB and cancer—identifying targets and mechanisms

(2008) Willscott E Naugler et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE